Company profile
Cryomass Technologies Inc.
OTC: CRYM · Healthcare · Drug Manufacturers - Specialty & Generic
#1132 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 47GM —SS 31
v0.1 · 25/100 weight · pillars only
↑ disclosure history, listing tenure · ↓ operating margin, net margin
Methodology →Revenue TTM
$37.7k
Rev growth YoY (TTM)
-96.0%
Net income (FY)
-$13.0M
Employees
6
as of 2026-08-28
Market cap
$47.4k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$13.6k$13.6k2023
Net income-$13.0M-$13.0M2023
Operating income-$10.8M-$10.8M2023
Total assets$972.5k$972.5k2023
Liabilities$6.8M$6.8M2023
Equity-$5.8M-$5.8M2023
Revenue trend
FY2014 – FY2023 · USD
FY14
FY15
FY16
FY18
FY18
FY19
FY20
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cryomass Technologies Inc.’s revenue?
Cryomass Technologies Inc. booked $13.6k in FY2023 revenue, contracting 98% year over year — among the slowest-growing Healthcare companies we track, at a -95600.1% net margin.
Peers · Healthcare
Nass Valley Gateway Ltd.——Premier Biomedical, Inc.——Wuhan General Group (China), Inc.——Relmada Therapeutics, Inc.38DThe Greater Cannabis Company, Inc.14DEvolutionary Genomics, Inc.——Neighbors
Denver →Key facts
CEOChristian Noel
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersDenver, CO
ExchangeOTC: CRYM
Employees6
IPO date2014-06-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.